Author Correction: Ablation of TRIP-Br2, a regulator of fat lipolysis, thermogenesis and oxidative metabolism, prevents diet-induced obesity and insulin resistance - Report - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Correction Notice: Inhibition of TRIP-Br2, a key modulator of lipid breakdown, thermogenic activity, and oxidative processes, mitigates obesity and insulin resistance linked to diet.

  • By

  • Chong Wee Liew

  • Jeremie Boucher

  • Jit Kong Cheong

  • Cecile Vernochet

  • Ho-Jin Koh

  • Cristina Mallol

  • Kristy Townsend

  • Dominique Langin

  • Dan Kawamori

  • Jiang Hu

  • Yu-Hua Tseng

  • Marc K Hellerstein

  • Stephen R Farmer

  • Laurie Goodyear

  • Alessandro Doria

  • Matthias Blüher

  • Stephen I-Hong Hsu

  • Rohit N Kulkarni

  • September 9, 2026

Share

Correction Notice: Inhibition of TRIP-Br2 Mitigates Obesity and Insulin Resistance

Overview

This correction notice addresses two errors in the supplementary information of a study on TRIP-Br2's role in lipid breakdown and obesity. The corrected figures clarify the protein plot and oil-red-O-stained images related to adipocyte cells.

Background

Understanding the mechanisms of obesity and insulin resistance is critical due to their association with chronic diseases such as type 2 diabetes and cardiovascular conditions. Accurate data representation is essential for the integrity of research findings in this field.

Data Highlights

No numerical or trial data is presented in the correction notice.

Key Findings

  • The label on the protein plot in Supplementary Fig. 3a was corrected from 'Epi/HF' to 'SQ/HF.'
  • Supplementary Fig. 12c contained incorrect images of oil-red-O-stained adipocyte cells, which have now been amended.
  • The errors were identified in the supplementary information of a study published in Nature Medicine.

Clinical Implications

The correction of these figures ensures that researchers and clinicians have access to accurate data regarding TRIP-Br2's role in obesity and insulin resistance.

Conclusion

The correction notice highlights the importance of accurate data representation.

Related Resources & Content

  1. Nature Medicine, 2013 -- Correction Notice: Inhibition of TRIP-Br2, a key modulator of lipid breakdown, thermogenic activity, and oxidative processes, mitigates obesity and insulin resistance linked to diet.
  2. Frontiers in Endocrinology — Acute TRPTI™ (oleoylethanolamide) supplementation enhances incretin hormone responses: a fixed-sequence crossover study
  3. the medicine maker — CRISPRing Up Brown Fat
  4. Frontiers in Endocrinology — Effects of tirzepatide therapy on body weight and body composition in adults with overweight and obesity
  5. the medicine maker — Rethinking Weight Loss Treatments
  6. 8.Obesity and WeightManagement for the Preventionand Treatment of Diabetes:Standards of Care inDiabetes–2026
  7. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity - PubMed
  8. Ablation of TRIP-Br2, a regulator of fat lipolysis, thermogenesis and oxidative metabolism, prevents diet-induced obesity and insulin resistance | Nature Medicine

Original Source(s)

Author Correction: Ablation of TRIP-Br2, a regulator of fat lipolysis, thermogenesis and oxidative metabolism, prevents diet-induced obesity and insulin resistance

  • by Chong Wee Liew, Jeremie Boucher, Jit Kong Cheong, Cecile Vernochet, Ho-Jin Koh, Cristina Mallol, Kristy Townsend, Dominique Langin, Dan Kawamori, Jiang Hu, Yu-Hua Tseng, Marc K Hellerstein, Stephen R Farmer, Laurie Goodyear, Alessandro Doria, Matthias Blüher, Stephen I-Hong Hsu, Rohit N Kulkarni

  • September 9, 2026

Related Content

Publisher Correction: Enhancing Postoperative Outcomes After Metabolic Bariatric Surgery: a Pilot Study of Inhibitory Control Training, Transcranial Direct Current Stimulation and Psychosocial Aftercare

Further Reflections on Metabolically Healthy Obesity in Children

Beyond lipids: a precision prevention blueprint for China's residual risk